Satellite meetings will be taking place on Sunday, August 21st (unless otherwise indicated) and are open to registrants of WC8.

To attend these sessions, you may contact the meeting organizer(s) directly via the emails below, providing your name and the email address that you provided upon registration.

CCAC sponsored session: Reduction and Refinement Through Good Design and Monitoring

Minimising numbers and severity in animal experiments involves choosing the approach that carries minimal severity and best fits the objectives at each stage.  This means having scope, on an experiment by experiment basis, to decide the most efficient design and to change procedures to ones of lesser severity in the light of experience.  Those approving programmes or protocols with such flexibility are likely to need reassurance that researchers are making suitable choices in practice and that post-approval monitoring systems can confirm this.

This workshop will be a mix of presentations and group work and is intended to cater for both researchers and those involved in approval and monitoring. For researchers the aim will be to explore how experimental design and practice can minimise numbers and severity, and simple ways of showing this.  For those involved in ethical review, the aim will be to help them appreciate key features in good design and practice and how the information provided by researchers can help them in evaluation and post-approval monitoring.

This full day session will be led by Dr. Derek Fry with the assistance of Ms. Michelle Hudson. Dr Fry has been running or contributing to workshops on experimental design, protocol assessment, or refinement in Europe, North America and Asia since 1999, and is experienced at making them interesting and informative for participants from a variety of backgrounds.  He is a medical academic who was Chief Inspector of the UK Animal Scientific Procedures Inspectorate until his retirement in 2008.  As well as inspecting experimental work on animals for nearly 20 years he has personally assessed over 1000 programmes of work.  Those who attended last year’s CCAC National Workshop may remember him as one of the key speakers.

Session also facilitated in French.

• Full day session

Deborah Biehler (Canadian Council on Animal Care)

Alternatives to the Pertussis Test

The goals of this satellite meeting are to (a) update participants on new research and the outcomes of recent workshops on alternative safety testing strategies for acellular pertussis vaccines, and (b) provide an opportunity to discuss regulatory criteria which these alternative methods may be required to meet.

Most regulators require the use of a mouse histamine sensitization test (HIST) to assay for residual pertussis toxin activity in acellular pertussis vaccines.  The traditional HIST is a non-quantitative lethal end-point assay which can be difficult to conduct, has a high false-positive outcome, and can require a large number of animals.

A modified HIST has been developed which monitors body temperature change as its end-point, although this method is not widely validated.  Similarly, various in vitro assays have been developed in recent years which measure specific biochemical or cellular functions of pertussis toxin; however, these methods are not validated and questions remain as to whether they are sufficient for monitoring vaccine safety.

This meeting is open to research scientists and regulators with an interest in the safety testing of acellular pertussis vaccines.

• Half-day session

Richard Isbrucker (Health Canada)

CAAT and the Human Toxicology Project (HTP) Consortium

This informal meeting focuses on the diverse efforts to implement 21st Century Toxicology, including the proposal in the 2007 report by the U.S. National Research Council on “Toxicity Testing in the 21st Century.” Attendees are invited to provide brief updates on their projects, whether in the realm of science, technology, policy, conceptual development, or coordination.   A projector and computer will be available for those wishing to show a few slides as part of their presentation.  The meeting is hosted by the Johns Hopkins Center for Alternatives to Animal Testing and the Human Toxicology Project Consortium. 

• Half-day session

Marilyn Principe (Centre for Alternatives to Animal Testing, US)             

Animal Protection Meeting

This meeting provides an opportunity for members of animal protection organizations to meet each other, learn about ongoing efforts, and discuss emerging issues and projects.  The meeting is being coordinated by the Humane Society family of organizations (Humane Society of the United States, Humane Society International, Humane Society Legislative Fund), Eurogroup for Animals, Animal Alliance of Canada, and the Alternatives Research and Development Foundation.

• Half-day session

Dawn McPherson (Humane Society of the United States)

The CeeTox Repeat Dose Systemic Toxicity Panel (CeeTox RDST Panel)

Presented by J.M. McKim Jr., PhD, DABT

The safety evaluation of cosmetics, personal care products and drugs is a crucial part of product development. Historically, standard tests for repeat dose systemic toxicity have been in vivo tests using animals as test systems. The Cosmetic Products Regulation, EU Regulation 1223/2009, requires the development of in vitro methods to replace animal methods and, for repeat dose systemic toxicity, be in place by 2013. While there are major initiatives underway to develop new in vitro models to assess systemic toxicity, none is expected to be scientifically validated before 2013. One exception may be the CeeTox RDST Panel, currently under development.

This screen uses a systems biology approach that focuses on multiple biochemical endpoints, over a wide range of exposure concentrations. By building a temporal component into the analysis, it is possible to identify the most sensitive subcellular target of toxicity.

The assay predicts a threshold plasma concentration for toxicity (CTox®). The Ctox value was established against the 14-day repeat dose study routinely performed in rats. In addition, CeeTox has demonstrated that a relationship exists between the CTox value and the maximum therapeutic plasma concentration (MTPC) achieved during the course of drug therapy in humans. MPTC can be estimated based on exposure, physical chemical properties, and ADME parameters, which can be obtained from in vitro models.

The RDST panel was developed and scientifically validated against both animal and human in vivo data. Ongoing efforts are focused on evaluating the assay's performance over a broader chemical space and its ability to predict toxicity in the rodent 28 day or 90 day studies. To our knowledge this new approach represents the first in vitro model designed to predict repeat dose systemic toxicity.

• 1 hour session, followed by reception

Jean Harden (CeeTox, Inc)

Altweb Project Team meeting

CAAT manages Altweb, the Alternatives to Animal Testing Website, on behalf of a 26-member international Project Team. The purpose of this meeting is to invite Project Team members to offer feedback and advice to help keep the site as informative, up-to-date, user-friendly, and visually appealing as possible. Project Team members  may also suggest (and/or help develop) new sections or resources for the site.

Moderators: Mike Hughes & Carol Howard (CAAT)

• Monday, August 22nd (2 hours)

Closed meeting. 
If an organization would like to join the Project Team, please contact Carol Howard (Centre for Alternatives to Animal Testing) at

Meeting of Three Rs Organizations

This meeting is intended primarily to bring together representatives of Three Rs organization from around the world to get to know each other, to discuss common issues and concerns, and to find ways to work together to advance the Three Rs and promote the most humane science possible.

• 1 ½ hours

Closed meeting. 
If an organization would like to join the Three Rs organizations meeting please contact Michael Hughes (Centre for Alternatives to Animal Testing) at